Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/86—Viral vectors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/145—Orthomyxoviridae, e.g. influenza virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/275—Poxviridae, e.g. avipoxvirus
  • A61K39/285—Vaccinia virus or variola virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/62—DNA sequences coding for fusion proteins
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
  • A61K2039/5256—Virus expressing foreign proteins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
  • A61K2039/5258—Virus-like particles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/70—Multivalent vaccine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/24011—Poxviridae
  • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
  • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/24011—Poxviridae
  • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
  • C12N2710/24123—Virus like particles [VLP]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/24011—Poxviridae
  • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
  • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/24011—Poxviridae
  • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
  • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
  • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
  • C12N2760/00011—Details
  • C12N2760/16011—Orthomyxoviridae
  • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
  • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

• the present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses.
• the invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara.
• the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.
• Human influenza or "the flu” is a respiratory disease that is caused by influenza A and B viruses. Epidemics of influenza cause significant illness and death worldwide each year, and vaccination is the most straightforward strategy to prevent infection and disease.
• Traditional influenza vaccines expose the recipient to influenza virus proteins causing the recipient to mount an immune response to the proteins. Proteins (or polypeptides ) used in vaccines are commonly called “antigens.”
• the commonly used seasonal influenza vaccines are based on the major antigen of the viruses, the hemagglutinin (HA).
• HA hemagglutinin
• Influenza A subtypes are divided and classified based on the HA and neuraminidase (NA) proteins that are expressed by the viruses.
• influenza A subtype nomenclature is based on the HA subtype (of the sixteen different HA genes known in the art) and the NA subtype (of the nine different NA genes known in the art).
• exemplary subtypes include, but are not limited to, H5N1, HlNl and H3N2.
• strains There are also variants of the influenza A subtypes which are referred to as "strains.”
• the virus A/VietNam/ 1203/2004 is an influenza A virus, subtype H5N1, with a strain name A/VietNam/1203/2004.
• the current 'universal vaccines' ⁇ i.e., vaccines designed to elicit heterosubtypic immunity) that are under development are mainly based on the more conserved internal influenza virus genes including the influenza matrix proteins (Ml and M2) (Schotsaert et al. 2009), the nucleoprotein (NP) and conserved parts of the HA (Bommakanti et al. 2010; Steel et al. 2010).
• the polymerase proteins PA, PB1 and PB2 also induce substantial T cell responses and may be also relevant targets (Assarsson et al. 2008; Greenbaum et al. 2009; Lee et al. 2008).
• Next generation influenza vaccines currently under development include recombinant proteins, synthetic peptides, virus-like particles (VLPs), DNA-based vaccines and viral vector vaccines (Lambert and Fauci, supra).
• VLPs virus-like particles
• viral vector vaccines Lambert and Fauci, supra.
• the advantage of using live viral vectors is their known property to induce high levels of cellular immunity, in particular CD8 T cells.
• viral vectors include vaccinia virus-based live vaccines (Rimmelzwaan and Sutter 2009) and adenovirus-based vectors (Hoelscher et al. 2006; Hoelscher et al. 2007; Price et al. 2010; Zhou et al. 2010).
• DNA vaccination with nucleoprotein (NP) and matrix 2 (M2) plasmids followed by boosting with antigen-matched recombinant adenovirus (rAd) provided robust protection against virulent HlNl and H5N1 challenges in mice and ferrets.
• MVA modified vaccinia virus Ankara
• MVA-based vaccines have been used in clinical studies, for instance, against HIV, tuberculosis, malaria and cancer. In all of these studies, at least two doses were used.
• the human dose of an MVA-based vaccine was 5x10 7 to 5x108 PFU as applied in clinical trials ( Brookes et al. 2008; Cebere et al. 2006;Tykodi and Thompson 2008;).
• MVA has been used recently as a vector in pandemic H5N1 (Kreijtz et al. 2008;
• the present invention provides recombinant viruses (also referred to as recombinant viral vectors herein) useful for generating a heterosubtypic immune response to influenza A viruses.
• the recombinant viruses are recombinant vaccinia viruses, such as recombinant MVA or other non-replicating or replicating vaccinia virus known in the art.
• Non-replicating vaccinia viruses include, but are not limited to, defective vaccinia Lister (dVV), MVA-575 (ECACC V00120707), MVA-BN (ECACC V00083008), MVA-F6 and MVA-M4 (Antoine et al. 1998).
• the recombinant viruses encode a fusion protein (hlHA/M2e) comprising an influenza A hemagglutinin deletion mutant "headless HA" (hlHA) with at least one influenza A M2 external domain (M2e) insert; an hlHA/M2e fusion protein and an influenza A
• the recombinant viruses of the invention may further encode an influenza A matrix protein 1 (Ml) and/or an influenza A polymerase PB1.
• Ml matrix protein 1
• PB1 influenza A polymerase PB1.
• the recombinant viruses are cross-protective and induce heterosubtypic humoral and cellular immune responses (including CD8 and CD4 T cell responses).
• the recombinant viruses are therefore contemplated to be useful as universal influenza A vaccines in humans.
• the hlHA amino acid sequence encoded by an open reading frame in recombinant viruses of the invention may be, for example, the hlHA amino acid sequence set out in SEQ ID NO: 15 (based on A/VietNam/ 1203/2004 H5N1 HA NCBI Genbank AAW80717 which is SEQ ID NO: 3).
• the hlHA of SEQ ID NO: 15 comprises a signal sequence, the HA1 residues 17-58 of SEQ ID NO: 3, a linker peptide of four glycines, the HA1 residues 290-343 of SEQ ID NO: 3 and the HA2 stalk region residues 344-568 of SEQ ID NO: 3.
• the hlHA/M2e fusion protein amino acid sequence encoded by an open reading frame in recombinant viruses of the invention may be, for example, the hlHA/M2e fusion protein amino acid sequence set out in SEQ ID NO: 2.
• the fusion protein of SEQ ID NO: 2 comprises a signal sequence, the HA1 residues 17-58 of SEQ ID NO: 3, a linker peptide of three glycines (SEQ ID NO: 4), the M2e of H5N1 (SEQ ID NO: 5 based on
• the hlHA/M2e fusion protein may comprise one, two, three or four of the M2e polypeptides of SEQ ID NOs: 5, 6, 7 and 8.
• the hlHA/M2e fusion protein may comprise an influenza A M2e polypeptide other than an M2e polypeptide of SEQ ID NOs: 5, 6, 7, and 8.
• the NP amino acid sequence encoded by an open reading frame in recombinant viruses of the invention may be, for example, the NP amino acid sequence set out in SEQ ID NO: 13 (based on A/VietNam/ 1203/2004 H5N1 NP NCBI Genbank AAW80720).
• the Ml amino acid sequence encoded by an open reading frame in recombinant viruses of the invention may be, for example, the Ml amino acid sequence set out in SEQ ID NO: 11 (based on A/VietNam/ 1203/2004 H5N1 Ml Genbank AAW80726).
• the PB 1 amino acid sequence encoded by an open reading frame in recombinant viruses of the invention may be, for example, the PB 1 amino acid sequence set out in SEQ ID NO: 17 (based on A/VietNam/ 1203/2004 H5N1 PB1 Genbank AAW80711).
• polypeptides encoded by an open reading frame in a recombinant virus may vary in sequence from SEQ ID NO: 2, 5, 6, 7, 8, 11, 13, 15 and/or 17 if the polypeptides retain the ability to induce a protective immune response when the recombinant virus is administered to an individual.
• the polypeptide may be about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 95%, about 97%, about 98% or about 99% identical to SEQ ID NO: 2, 5, 6, 7, 8, 11, 13, 15 and/or 17 .
• hlHA/M2e fusion proteins, hlHA polypeptides and NP polypeptides encoded by recombinant viruses of the invention may be based on the same or different influenza A subtypes including, but not limited to, any combination of HI to H16 and Nl to N9 (including HlNl, H2N1, H3N1, H4N1, H5N1, H6N1, H7N1, H8N1, H9N1, H10N1, H11N1, H12N1, H13N1, H14N1, H15N1, H16N1 ; H1N2, H2N2, H3N2, H4N2, H5N2, H6N2, H7N2, H8N2, H9N2, H10N2, H11N2, H12N2, H13N2, H14N2, H15N2, H16N2; H1N3, H2N3, H3N3, H4N3, H5N3, H6N3, H7N3, H8N3, H9N3, H10
• a list of identified Influenza A strains is available from the World Health Organization (WHO) and United States Centers for Disease Control (CDC) databases of Influenza A subtypes.
• the National Center for Biotechnology Information (NCBI) database maintained by the United States National Library of Medicine also maintains an updated database describing the length and sequence of HA, M2, NP, Ml and PB1 genes of viruses of influenza A species.
• Strains listed by these organizations and strains described in other commercial and academic databases, or in literature publications and known in the art, are contemplated for use in the invention. It is also contemplated that additional influenza A strains hereafter identified and isolated are also useful in the invention as sources of influenza A protein sequences.
• any strain specifically exemplified in the specification and those known or after discovered in the art are amenable to the recombinant vaccinia virus, pharmaceutical compositions, and methods of the invention.
• Exemplary strains include, but are not limited to, the strains in Table 1 below. The table also lists exemplary genes and associated database accession numbers of those strains.
• open reading frames encoding hlHA/M2e, hlHA, NP, Ml and/or PB1 may be codon-optimized for expression in human cells.
• one or more (or all) of the naturally occurring codons in an open reading frame have been replaced in the codon-optimized open reading frame with codons frequently used in genes in human cells (sometimes referred to as preferred codons).
• Codons may be optimized to avoid repeat sequences to stabilize an open reading frame in the rMVA and/or to avoid unwanted transcription stop signals. Codon-optimization, in general, has been used in the field of recombinant gene expression to enhance expression of polypeptides in cells.
• Gene cassettes encoding hlHA/M2e, hlHA, NP, Ml and PB1 in recombinant viruses of the invention include an open reading frame under the control of (i.e., operatively linked to) a promoter that functions (i.e., directs transcription of the open reading frame) in the recombinant vaccinia viruses.
• expression from gene cassettes is under the control of the strong early/late vaccinia virus mH5 promoter (SEQ ID NO: 18) or the synthetic early/late selP promoter (SEQ ID NO: 19) (Chakrabarti et al. 1997).
• the open reading frame is also operatively linked to a transcription stop signal such as a vaccinia virus early transcription stop signal.
• the invention provides recombinant vaccinia virus comprising a gene cassette encoding an influenza A hlHA/M2e fusion protein.
• the recombinant vaccinia virus is a recombinant MVA comprising a gene cassette expressing the hlHA/M2e fusion protein set out in SEQ ID NO: 2.
• the recombinant vaccinia virus further comprises a gene cassette expressing the Ml protein (for example, the Ml set out in SEQ ID NO: 11) and/or a gene cassette expressing the PB1 protein (for example, the PB1 protein set out in SEQ ID NO: 17).
• the invention provides recombinant vaccinia virus comprising a first gene cassette encoding an influenza A hlHA/M2e fusion protein, and a second gene cassette encoding an influenza NP.
• the recombinant vaccinia virus is a recombinant MVA comprising a first gene cassette expressing the hlHA/M2e fusion protein set out in SEQ ID NO: 2 and a second gene cassette expressing the NP set out in SEQ ID NO: 13.
• the recombinant vaccinia virus further comprises a gene cassette expressing the Ml protein (for example, the Ml set out in SEQ ID NO: 11) and/or a gene cassette expressing the PB1 protein (for example, the PB1 protein set out in SEQ ID NO: 17).
• the invention provides recombinant vaccinia virus comprising a first gene cassette encoding an influenza A hlHA and a second gene cassette encoding an influenza NP.
• the recombinant vaccinia virus is a recombinant MVA comprising a first gene cassette expressing the hlHA set out in SEQ ID NO: 15 and a second gene cassette expressing the NP set out in SEQ ID NO: 13.
• the recombinant vaccinia virus further comprises a gene cassette expressing the Ml protein (for example, the Ml set out in SEQ ID NO: 11) and/or a gene cassette expressing the PB1 protein (for example, the PB1 protein set out in SEQ ID NO: 17).
• the gene cassettes may be inserted in non-essential regions of the vaccinia virus genome, such as the deletion I region, the deletion II region, the deletion III region, the deletion IV region, the thymidine kinase locus, the D4R/5R intergenic region, or the HA locus.
• the insertion of the hlHA/M2e and hlHA gene cassettes is in the D4R/5R intergenic region and the insertion of the NP gene cassette is in the deletion III region.
• the recombinant MVA is derived from an MVA free of bovine spongiform encephalopathy (BSE) such as MVA74 LVD6 obtained from the National Institutes of Health.
• BSE bovine spongiform encephalopathy
• the recombinant viruses of the invention may be formulated as pharmaceutical compositions according to methods known in the art. In some embodiments, the recombinant viruses are formulated as described in International Publication No. WO 2010/056991.
• the invention provides methods of inducing a heterosubtypic influenza A immune response in an individual comprising administering compositions of recombinant vaccinia virus of the invention to the individual.
• the composition may be administered as a single dose, a double dose or multiple doses.
• the administration route in humans may be inhalation, intranasally, orally, and parenterally. Examples of parenteral routes of administration include intradermal, intramuscular, intravenous, intraperitoneal and subcutaneous administration.
• the range of the human immunization dose may be about 10 6 to about 10 9 PFU.
• the methods of the invention induce humoral and cellular immune responses in the individual.
• the methods induce a protective immune response in the individual.
• the protective immune response may be where the individual exhibits no symptoms of infection, a reduction in symptoms, a reduction in virus titer in tissues or nasal secretions, and/or complete protection against infection by influenza virus.
• kits for administering recombinant vaccinia virus of the invention packaged in a manner which facilitates their use to practice methods of the invention includes a recombinant virus or composition described herein, packaged in a container such as a sealed bottle or vessel, with a label affixed to the container or included in the package that describes use of the compound or composition in practicing the method.
• the recombinant virus or composition is packaged in a unit dosage form.
• the kit may further include a device suitable for administration according to a specific route of administration or for practicing a screening assay.
• the kit contains a label that describes use of the recombinant vaccinia virus.
• the kit comprises instructions for administration to a human subject.
• the methods comprise the steps of: a) infecting primary chicken embryo cells or a suitable permanent cell line (e.g., avian) with MVA, b) transfecting the infected cells with a plasmid comprising the gene cassette and comprising DNA flanking the gene cassette that is homologous to a non-essential region of the MVA genome, c) growing the cells to allow the plasmid to recombine with the MVA genome during replication of the MVA in chicken cells thereby inserting the gene cassette into the MVA genome in the non-essential region, and d) obtaining the recombinant MVA produced.
• a suitable permanent cell line e.g., avian
• the non-essential MVA region is the deletion I region, the deletion II region (Meyer et al. 1991), the deletion III region (Antoine et al. 1996), the deletion IV region (Meyer et al., supra; Antoine et al. 1998) the thymidine kinase locus (Mackett et al. 1982), the D4R/5R intergenic region (Holzer et al. 1998), or the HA locus (Antoine et al. supra).
• the insertion is in the deletion III region. In another exemplified embodiment, the insertion is in the D4R/5R intergenic region. If two gene cassettes are to be inserted, the two are inserted in different non-essential regions. Gene cassettes may additionally be inserted into any other suitable genomic region or intergenomic regions.
• vertebrate cell lines are useful for culture and growth of vaccinia virus of the invention.
• exemplary vertebrate cells useful to culture vaccinia virus of the invention include, but are not limited to, MRC-5, MRC-9, CV-1 (African Green monkey), HEK (human embryonic kidney), PerC6 (human retinoblast), BHK-21 cells (baby hamster kidney), BSC (monkey kidney cell), LLC-MK2 (monkey kidney) and permanent avian cell lines such as DF-1.
• Vero cells are an accepted cell line for production of viral vaccines according to the World Health Organization. In some embodiments, recombinant replicating vaccinia virus of the invention are produced in Vero cells.
• Figure 1 shows the amino acid sequence (SEQ ID NO: 15) of the headless HA protein encoded by recombinant MVA (rMVA) of the invention.
• the protein contains a signal sequence (grey), HA1 residues (red), a linker peptide of four glycines (black), HA1 residues (red), and the HA2 stalk region (black).
• Cysteines 58 and 63 and the polybasic cleavage site are underlined.
• Figure 2 shows the nucleotide sequence (SEQ ID NO: 14) of the headless HA protein encoded by rMVA of the invention.
• Figure 3 shows the amino acid sequence (SEQ ID NO: 2) of headless HA/M2e fusion protein.
• the designed protein contains a signal sequence (grey), HA1 residues (red), a linker peptide of three glycines (black), the M2e of H5N1 (blue), the six amino acid linker GSAGSA (black), the M2e of H1N1 (equivalent to H2N2, H3N2; green), the six amino acid linker
• GSAGSA the M2e of H9N2 (orange), the six amino acid linker GSAGSA, the M2e of H7N2 (pink), a linker peptide of three glycines (black), HA1 residues (red) and the HA2 stalk region (black).
• the polybasic cleavage site (amino acids 224-231) is underlined.
• Figure 4 shows the nucleotide sequence (SEQ ID NO: 1) of the headless HA/M2e fusion protein encoded by rMVA of the invention.
• Figure 5 shows single-insert rMVAs containing influenza genes.
• Figure 5A indicates the hlHA, hlHA/M2e, M2, PB1, or Ml gene cassettes that are located in the recombinant MVA D4R/D5R intergenic locus, at the position corresponding to nucleotide 87,281 of wild type MVA (Antoine et al, supra).
• Figure 5B indicates the NP gene cassette is located in the del 111 locus at the position corresponding to nucleotide 142,992 of wild type MVA.
• Figure 6 shows a Western Blot of chicken cell lysates tested for influenza virus antigens.
• Figure 7 shows double-insert rMVAs containing influenza genes.
• the hlHA or hlHA/M2e gene cassette is located in the D4R/D5R intergenic locus, at the position
• the NP gene cassette is located in the del 111 locus at the position corresponding to nucleotide 142,992 of the wild type MVA.
• Figure 8 shows a Western Blot of chicken cell lysates tested for influenza virus antigens.
• the hlHA/M2e fusion protein expressed by MVA-hlHA/M2e is visible at around 70 kDa (lane 5).
• the lower bands at around 40 kDa represent the hlHA expressed by MVA-hlHA-NP and MVA-hlHA.
• the control construct (MVA- HA-VN), expressing the full length HA protein express the HAO (band around 80 kDa), the HAl (band around 55 kDa, and the HA2 (band around 25 kDa).
• the expression of the HA2 protein is also visible in lanes 3, 5 and 6 as the hlHA and hlHA/M2e proteins also contain the polybasic cleavage site.
• the specific HA bands are absent in the negative control (lane 4).
• Lane 1 protein ladder, size in kDa; lane 2, MVA-D3-NP-VN; lane 3, MVA-hlHA-NP; lane 4, MVA-hlHA/M2e-NP; and lane 5, MVA wt (negative control).
• Figure 9 shows monitoring of weight (A, B), clinical symptoms (C, D) and survival (E, F) after vaccination with recombinant MVAs and challenge with H5N1.
• mice were vaccinated with MVA-HA-VN, expressing the full-length HA of A/Vietnam/ 1203/2004, wt MVA or were treated with PBS (panels A, C, E).
• Mice were vaccinated with the single recombinant MVA-hlHA, MVA-hlHA/M2e, MVA-NP-VN or the double recombinants MVA- hlHA-NP and MVA-hlHA/M2e-NP (panels B, D, F).
• mice were monitored for 14 days.
• FIG 10 shows monitoring of weight (A, B), clinical symptoms (C, D) and survival (E, F) after vaccination with recombinant MVAs and challenge with H9N2 virus.
• mice were vaccinated with the whole virus preparation of H9N2, wt MVA or were treated with PBS (panels A, C, E).
• Mice were vaccinated with the single recombinant MVA-hlHA, MVA- hlHA/M2e, MVA-NP-VN or double recombinant MVA-hlHA-NP and MVA-hlHA/M2e-NP (panels B, D, F).
• mice were monitored for 14 days.
• Figure 11 shows triple-insert rMVAs containing influenza genes.
• the hlHA or hlHA/M2e and Mlgene cassettes will be located in the D4R/D5R intergenic locus, at the position 87,281 nt of the wt MVA sequence.
• the NP gene cassette will be located in the del 111 locus at the position 142,992 nt of the wt MVA sequence.
• Example 1 describes the choice and design of influenza A antigens in exemplary recombinant MVA of the invention
• Example 2 details the production of single-insert recombinant MVAs
• Example 3 describes animal experiments with the single-insert MVAs
• Example 4 details the production of double-insert recombinant MVAs
• Example 5 describes animal experiments with the double- insert MVAs
• Example 6 details the production of triple-insert recombinant MVAs
• Example 7 describes animal experiments with the triple-insert MVAs.
• Influenza headless HA, a headless HA/M2e fusion protein, NP, Ml, M2 and PB1 were the influenza A antigens chosen to be encoded by exemplary recombinant MVA of the invention.
• Monoclonal antibodies against the HA stalk domain, the HA2 region are broadly cross-reactive and neutralize several subtypes of viruses (Ekiert et al. 2009; Kashyap et al. 2008; Okuno et al. 1993; Sanchez-Fauquier et al. 1987; Sui et al. 2009; Throsby et al. 2008).
• the antibodies target the HA2 region of the molecule and presumably act by preventing the conformational change of HA at low pH, thus presumably blocking fusion of viral and host membranes during influenza infection.
• HA2 immunogen has proven to be difficult, owing to the metastable nature of HA (Chen et al. 1995).
• a headless HA was chosen as an antigen.
• the headless HA consists of two HA1 regions that interact with an HA2 subunit, stabilizing the neutral pH conformation (Bommakanti et al., supra; Steel et al., supra).
• M2e The extracellular domain of the M2 protein (M2e, 23 AS) is highly conserved across influenza A virus subtypes. In animals, M2e specific antibodies reduce the severity of infection with a wide range of influenza A virus strains (Fan et a/.2004; Neirynck et al. 1999). Many groups have reported M2e-based vaccine candidates in different forms (De Filette et al. 2008; Denis et al. 2008; Eliasson et al. 2008; Fan et al., supra; Neirynck et al., supra). Recently, Zhao et al.
• Vaccination using vectors expressing the conserved influenza NP, or a combination of NP and matrix protein has been studied in animal models and various degrees of protection against both homologous and heterologous viruses have been demonstrated (Price et al., supra; Ulmer et al. 1993).
• NP elicit a robust CD8 + T cell response in mice and in humans (McMichael et al., 1986; Yewdell et al., 1985) that, as epidemiological studies suggest, may contribute to resistance against severe disease following influenza A virus infection (Epstein 2006).
• the headless HA included in rMVA of the invention is a new headless HA (hlHA) based on the VN/1203 influenza strain.
• the hlHA contains a polybasic cleavage site which is cleaved during expression from the rMVA exposing the fusion peptide for the immune system.
• the amino acid sequence of the hlHA is set out in Figure 1 and in SEQ ID NO: 15.
• the nucleotide sequence of the MVA insert is set out Figure 2 and SEQ ID NO: 14.
• the amino acid sequence of the headless HA/M2e fusion protein included in rMVA of the invention is set out in Figure 3 below and in SEQ ID NO: 2.
• the nucleotide sequence of the fusion protein is set out in Figure 4 below and in SEQ ID NO: 1.
• the M2e domains of H5N1, H9N2, H7N2 and H1N1 form an M2e "head" on the hlHA.
• the four particular M2e domains were chosen to represent the M2e from seasonal and pandemic strains.
• rMVA recombinant MVA
• the hlHA, hlHA/M2e and PBl genes were chemically synthesized (Geneart, Inc., Regensburg, Germany). The synthetic genes are driven by the strong vaccinia early/late promoter mH5 (Wyatt et al. 1996) and terminated with a vaccinia virus specific stop signal downstream of the coding region that is absent internally.
• the gene cassettes were cloned in the plasmid pDM- D4R (Ricci et al., 2011) resulting in plasmids pDM-hlHA, pDM-hlHA/M2e and pDM-PBl-VN, respectively.
• the introduction of the foreign genes into the D4R/D5R intergenic region of MVA was done as described elsewhere (Ricci et al. 2011) resulting in viruses MVA-hlHA, MVA- hlHA/M2e, MVA-PB1-VN.
• the Ml sequence (accession number AY818144) was placed downstream of the strong vaccinia early/late promoter selP (Chakrabarti et al. 1997) and cloned in pDM-D4R, resulting in pDM-Ml-VN.
• the expression cassette of pDD4-M2-VN - including the M2 sequence (accession number EF541453) under the control of the mH5 promoter - was cloned in pDM-D4R resulting in pDM-M2-VN.
• the plasmids were then used for recombination with MVA according to Holzer et al, supra resulting in the viruses MVA-M1-VN and MVA-M2-VN, respectively as shown in Figure 5 A.
• Plasmid pd3-lacZ-gpt contains a lacZ/gpt selection marker cassette and a multiple cloning site (MCS) for insertion of genes of interest. The sequences are framed by genomic MVA sequences of the del III region.
• the marker cassette is destabilized by a tandem repeat of MVA del III flank, thus the final recombinant is free of any auxiliary sequences.
• the insertion plasmid directs the gene cassettes into the MVA deletion III (del III) region.
• Recombinant virus is selected using the transient marker stabilization method
• the single-insert MVA vectors expressing the NP, PB1, Ml, M2, hlHA, and hlHA/M2e were characterized by PCR and Western blot as described in Hessel et al, supra. Recombinant viruses were grown in CEC or DF-1 cells and purified by centrifugation through a sucrose cushion. Primary CEC were produced in-house and cultivated in Medl99 (Gibco®) supplemented with 5 % fetal calf serum (FCS). The DF-1 (CRL-12203) cell line was obtained from the ATCC (American Type Culture Collection) and cultivated in DMEM (Biochrom, Inc.) supplemented with 5 % FCS.
• the correct expression of the influenza proteins by the rMVAs was confirmed by Western blotting.
• CEC or the permanent chicken cell line DF-1 were infected with a MOI of 0.1 and cell lysates were prepared 48-72 hrs post infections.
• the recombinant MVAs that express the hlHA (MVA-hlHA and MVA-hlHA/M2e) were analyzed in a Western blot using an anti-influenza A/Vietnam/ 1194/04 (H5N1) polyclonal serum (NIBSC 04/214) for detection.
• Donkey-anti-sheep alkaline phosphatase-conjugated IgG was used as a secondary antibody.
• the recombinant MVAs that express the M2 and M2e were analyzed in Western Blots using an anti-avian influenza M2 antibody binding a peptide present at the amino terminus of the H5N1 M2 (ProSci, Cat# 4333). Goat-anti- rabbit alkaline phosphatase-conjugated IgG (Sigma Inc.) antibody was used as a secondary antibody.
• the recombinant MVAs expressing the hlHA (MVA-hlHA and MVA-hlHA/M2e) gene inserts induced expression of the HA containing antigens in avian DF-1 cells.
• the bands around 40 kDa in lane 2 represent the hlHA.
• the larger band at around 70 kDa in lane 3 represents the hlHA/M2e.
• the large band at around 80 kDa in lane 5 represents the HAO hemagglutinin-precursor, which is cleaved into the HAl and HA2 subunits represent by the bands at approximately 55 and 25 kDa.
• the specific hlHA, hlHA/M2e or HA bands are absent in the wild- type MVA control (lane 4).
• Figure 6B shows the M2 expression by MVA-M2-VN (lane 2) or MVA-hlHA/M2e (lane 3).
• the weak but specific band around 10 kDa in lane 2 represents the wild-type M2 protein whereas the larger band around 70 kDa represents the hlHA/M2e protein. Both bands are absent in the wild- type MVA control (lane 4).
• Ml, NP and PB1 protein are detected with polyclonal guinea-pig anti-influenza H5N1 serum produced in house, a polyclonal goat antibody detecting the PB1 of Influenza A virus (Santa Cruz, Cat#: vC-19), and a monoclonal mouse-anti-NP-antibody
• the MVA-M1-VN and MVA-NP-VN induce expression of the Ml protein (around 27 kDa) and the NP protein (around 60 kDa) (not shown).
• a standard protection experiment consists of two arms (primed with about 1x10 3 -1x105 TCID 50 HINlv CA/07 and unprimed) of nine groups of mice each (respectively vaccinated i.m. with lxlO 6 pfu of the nine vaccines and controls shown in Table 2), a group consisting of six animals resulting in 108 animals, defines one set. The animals of one set are challenged with one of the six challenge viruses shown in Table 3 below. Table 3
• mice Female Balb/c mice are 8-10 weeks old at the pre-treatment time point and 14-16 weeks old at the time point of immunization with the vaccines and controls shown in Table 2. Mice were immunized intramuscularly twice (days 42 and 63) with 10 6 pfu of the vaccines or wild type MVA, 3.75 ⁇ g whole virus preparation H9N2 A/HongKong/G9/1997 or with buffer (PBS). At day 84, mice were challenged intranasally with 10 3 TCID 50 H5N1
• A/Vietnam/1203/2004 H5N1, CDC #2004706280
• 2.5xl0 4 TCID50 mouse adapted H9N2 A/HongKong/G9/1997 or with 1.66xl0 4 TdD 5 o H7Nl A/FPV/Rostock/34.
• the challenge doses correspond to approx. 30 LD50 for the H5N1 challenge and 32 LD50 for the H9N2 challenge per animal.
• Sera are collected at days 41, 62 and 85 and analyzed for HA-specific IgG concentration by HI titer or microneutralization assay.
• the primary outcome of the animal experiments is protection as measured by lethal endpoint, weight loss, or lung titer. Further the ELISA titers of pooled pre-challenge sera measured against inactivated whole virus H5N1 strain A/Vietnam/1203/2004 are determined.
• Frequencies of influenza- specific CD4 and CD8 T cells are determined in immunized mice by flow cytometry.
• groups of 5 female BALB/c mice are immunized twice with the vaccines or controls listed in Table 2.
• Splenocytes are re-stimulated in-vitro using inactivated whole virus antigens of different influenza strains for CD4 T-cells and, when available, peptides representing the CD8 T-cell epitopes of the vaccine insert constructs and IFN- ⁇ production are measured. All experiments are performed twice, using a total of 140 animals. Other experiments
• the single insert MVA recombinants of Example 2 containing the hlHA or hlHA/M2e gene cassette are used.
• CEC cells were infected with MVA-hlHA or MVA-hlHA/Me2 and afterwards transfected with pd3-lacZ-mH5-NP-VN (see Example 2).
• Homologous recombination and propagation of the recombinant MVA vectors are performed as described in Example 2.
• the resulting double insert MVA vectors contain the hlHA or hlHA/M2e expression cassette in the D4R/D5R locus and the NP expression cassette in the del III locus. See Figure 7.
• FIG. 8A shows the expression of the hlHA and hlHA/M2e after infection of CEC with MVA-hlHA-NP (lane 6) or MVA-hlHA/M2e-NP (lane 5).
• the bands around 40 kDa in lanes 3 and 6 represent the hlHA of the MVA-hlHA and MVA-hlHA-NP constructs.
• the band around 70 kDa in lane 5 represents the hlHA/M2e fusion protein.
• the HA bands are absent in the wild- type control in lane 4.
• the same samples were used for detection of NP protein expression in Western Blots (as described in Example 2).
• the recombinant MVAs MVA-hlHA-NP and MVA-hlHA/M2e-NP also induced expression of the NP protein in avian CEC cells.
• the bands around 60 kDa in lanes 2 to 4 represent the NP.
• mice Animal experiments with the double-insert vaccines or vector combinations Protection experiment [0064]
• a standard experiment included eight groups of mice (vaccinated with the six vaccines and controls shown in Table 5) each group consisting of six animals.
• the protection experiments were carried out as described in Example 3. After challenge mice were monitored over a time period of 14 days and weight loss or symptoms including ruffled fur (score of 1), curved posture (score of 2), apathy (score of 3), and death (score of 4) were recorded. For ethical reasons, mice were euthanized after weight loss of >25 . Protection results are compiled in Table 5 and displayed in Figures 9 and 10.
• mice were vaccinated with homologous control constructs.
• H5N1 challenge mice were vaccinated with MVA-HA-VN (Hessel et ah, 2011) and in case of H9N2 challenge mice were vaccinated with an inactivated whole virus preparation of the H9N2 A/HongKong/G9/1997 influenza virus.
• Both controls induced full protection (Table 5; Figure 9 and 10, panels E).
• wild-type MVA and buffer groups all mice showed marked weight loss compared to the positive control groups and nearly all mice died after challenge.
• mice vaccinated with the single recombinant MVAs showed no significantly better protection after the strong H5N1 challenge compared to the negative control groups ( Figure 9 A-F). Also against heterosubtypic (H9N2) challenge no significant protection was seen in MVA-hlHA and MVA-hlHA/M2e vaccinated groups (Fig. 10).
• Frequencies of influenza-specific CD4 and CD8 T cells are determined in immunized mice by flow cytometry.
• groups of 5 female BALB/c mice are immunized twice with the vaccines or controls listed in Table 4.
• Splenocytes are re-stimulated in-vitro using inactivated whole virus antigens of different influenza strains for CD4 T-cells and, when available, peptides representing the CD8 T-cell epitopes of the vaccine insert constructs and IFN- ⁇ production are measured. All experiments are performed twice.
• VLPs Influenza virus-like particles induce humoral and cellular responses and can protect against lethal challenges (Bright et al. 2007; Pushko et al. 2005; Song et al. 2010).
• VLPs chosen for experiments herein comprise either hlHA or hlHA/M2e in combination with NP and Ml.
• the VLPs are generated from triple-insert MVA vectors.
• the Ml gene (SEQ ID NO: 10) of pDD4-Ml-VN is cloned downstream of the synthetic early/late promotor selP (Chakrabarti et al. 1997).
• the resulting gene cassette is cloned downstream of the hlHA or hlHA/M2e gene cassette in pDM-hlHA or pDM-hlH A/M2e .
• the resulting plasmids harboring a double gene cassette (pDM-hlHA-Ml and pDM-hlHA/M2e-Ml) are used for recombination into defective MVA as described above.
• a recombination with an NP gene cassette (SEQ ID NO: 12) -containing plasmid (pD3-lacZ-gpt-NP-VN) is done resulting in a triple-insert MVA virus.
• This triple-insert MVA is plaque purified under transient marker selection.
• the triple-insert MVA vectors named MVA-hlHA-Ml-NP or M VA-hlHA/M2e-M 1 - NP contain the hlHA or hlHA/M2e expression cassette and Ml expression cassette in tandem order in the D4R/D5R locus and the NP expression cassette in the del III locus ( Figure 7).
• Detection of VLPs is as follows. HeLa or 293 cells are seeded into T175cm 2 flasks and grown in DMEM + 10 FCS + Pen/Strep. To generate VLPs, cells are infected with 1 MOI of single-insert MVA or triple-insert MVA recombinants, respectively. Empty MVA vectors or single-insert MVA recombinants without Ml are used as controls. At lh post infection (p.i.), the medium is replaced by DMEM + Pen/Strep and culture medium is harvested 48h p.i. and cellular debris is pelleted by centrifugation at 2.000 x g for 10 min.
• a standard experiment includes 6 groups of primed and unprimed mice (vaccinated with the 6 vaccines and controls shown in Table 5), each group consisting of 6 animals, resulting in 36 animals (1 set). The animals are challenged with one of the 6 challenge viruses shown in Table 3. In sum, there are 6 sets of 72 animals each requiring 432 mice to assess cross- protection in the primed and naive models.
• Bommakanti G., M. P. Citron, R. W. Hepler, C. Callahan, G. J. Heidecker, T. A. Najar, X. Lu, J. G. Joyce, J. W. Shiver, D. R. Casimiro, J. ter Meulen, X. Liang, and R. Varadarajan. 2010.
• Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25:3871-8.
• HIV-1 human immunodeficiency virus type 1
• Influenza virus hemagglutinin requires palmitoylation of its cytoplasmic tail for assembly: Ml proteins of two subtypes differ in their ability to support assembly. J Virol 79: 13673-84.
• HA2 hemagglutinin
• CTA1-M2e-DD a novel mucosal adjuvant targeted influenza vaccine.
• Influenza virus matrix protein is the major driving force in virus budding. J Virol 74: 11538-47.
• New pre-pandemic influenza vaccines an egg- and adjuvant- independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin. Pharmacol. Ther. 82:665-671.
• hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 199:405-13.
• Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis. 195: 1598-1606.
• Vaccinia virus a selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. Sci. U. S. A 79:7415-7419.
• Influenza viruslike particles comprised of the HA, NA, and Ml proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.
• Throsby M., E. van den Brink, M. Jongeneelen, L. L. Poon, P. Alard, L. Cornelissen, A. Bakker, F. Cox, E. van Deventer, Y. Guan, J. Cinatl, J. ter Meulen, I. Lasters, R. Carsetti, M. Peiris, J. de Kruif, and J. Goudsmit. 2008. Heterosubtypic neutralizing monoclonal antibodies cross- protective against H5N1 and H1N1 recovered from human IgM-i- memory B cells. PLoS One 3:e3942.
• Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82: 1785-9.
• H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Genetics & Genomics (AREA)
• Chemical & Material Sciences (AREA)
• Virology (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Microbiology (AREA)
• Organic Chemistry (AREA)
• Biomedical Technology (AREA)
• Wood Science & Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Zoology (AREA)
• Medicinal Chemistry (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Immunology (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Molecular Biology (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Biochemistry (AREA)
• Pulmonology (AREA)
• Plant Pathology (AREA)
• Physics & Mathematics (AREA)
• Biophysics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Communicable Diseases (AREA)
• General Chemical & Material Sciences (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=45561167

Family Applications (1)

Country Status (6)

Cited By (4)

Families Citing this family (10)

Citations (3)

Family Cites Families (8)

• 2012
  • 2012-01-30 EP EP12702162.4A patent/EP2670430B1/en active Active
  • 2012-01-30 AU AU2012212463A patent/AU2012212463B2/en active Active
  • 2012-01-30 JP JP2013552568A patent/JP6169494B2/ja active Active
  • 2012-01-30 WO PCT/US2012/023085 patent/WO2012106231A2/en not_active Ceased
  • 2012-01-30 CN CN201280015880.9A patent/CN103458922B/zh active Active
  • 2012-01-30 US US13/982,524 patent/US9463237B2/en active Active
• 2016
  • 2016-09-30 AU AU2016235002A patent/AU2016235002B2/en active Active
  • 2016-10-07 US US15/289,106 patent/US10329583B2/en active Active
• 2017
  • 2017-06-28 JP JP2017126499A patent/JP6461244B2/ja active Active

Patent Citations (6)

Non-Patent Citations (68)

Also Published As

Similar Documents

Legal Events